Evidence map›Paper›PMID 38638480›Full record

ArticleFrontiers in public health2024

Mingzhu Sun, Jayne Moquet, Stephen Barnard, Hannah Mancey, David Burling, Rachel Baldwin-Cleland, Kevin Monahan, Andrew Latchford, David Lloyd, Simon Bouffler and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Mingzhu SunUnited Kingdom Health Security Agency, Department of Radiation Effects, Cytogenetics and Pathology Group, Radiation, Chemical and Environmental Hazards Directorate, Didcot, United Kingdom.
Jayne MoquetUnited Kingdom Health Security Agency, Department of Radiation Effects, Cytogenetics and Pathology Group, Radiation, Chemical and Environmental Hazards Directorate, Didcot, United Kingdom.
Stephen BarnardUnited Kingdom Health Security Agency, Department of Radiation Effects, Cytogenetics and Pathology Group, Radiation, Chemical and Environmental Hazards Directorate, Didcot, United Kingdom.
Hannah ManceyUnited Kingdom Health Security Agency, Department of Radiation Effects, Cytogenetics and Pathology Group, Radiation, Chemical and Environmental Hazards Directorate, Didcot, United Kingdom.
David BurlingIntestinal Imaging Centre, St Mark's Hospital, London North West University Healthcare National Health Service Trust, Harrow, United Kingdom.
Rachel Baldwin-ClelandIntestinal Imaging Centre, St Mark's Hospital, London North West University Healthcare National Health Service Trust, Harrow, United Kingdom.
Kevin MonahanLynch Syndrome Clinic, Centre for Familial Intestinal Cancer, St Mark's Hospital, London North West University Healthcare National Health Service Trust, Harrow, United Kingdom.
Andrew LatchfordLynch Syndrome Clinic, Centre for Familial Intestinal Cancer, St Mark's Hospital, London North West University Healthcare National Health Service Trust, Harrow, United Kingdom.
David LloydUnited Kingdom Health Security Agency, Department of Radiation Effects, Cytogenetics and Pathology Group, Radiation, Chemical and Environmental Hazards Directorate, Didcot, United Kingdom.
Simon BoufflerUnited Kingdom Health Security Agency, Department of Radiation Effects, Cytogenetics and Pathology Group, Radiation, Chemical and Environmental Hazards Directorate, Didcot, United Kingdom.
Christophe BadieUnited Kingdom Health Security Agency, Department of Radiation Effects, Cytogenetics and Pathology Group, Radiation, Chemical and Environmental Hazards Directorate, Didcot, United Kingdom.
Nicola A AnyameneEast and North Hertfordshire National Health Service Trust, Mount Vernon Cancer Centre, Northwood, United Kingdom.
Elizabeth AinsburyUnited Kingdom Health Security Agency, Department of Radiation Effects, Cytogenetics and Pathology Group, Radiation, Chemical and Environmental Hazards Directorate, Didcot, United Kingdom.
Public Health England · GBLondon North West Healthcare NHS Trust · GBImperial College London · GBMount Vernon Cancer Centre · GBNational Health Service · GBSt Mark's Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Lynch syndrome patients have an inherited predisposition to cancer due to a deficiency in DNA mismatch repair (MMR) genes which could lead to a higher risk of developing cancer if exposed to ionizing radiation. This pilot study aims to reveal the association between MMR deficiency and radiosensitivity at both a CT relevant low dose (20 mGy) and a therapeutic higher dose (2 Gy). Methods: Human colorectal cancer cell lines with (dMMR) or without MMR deficiency (pMMR) were analyzed before and after exposure to radiation using cellular and cytogenetic analyses i.e., clonogenic assay to determine cell reproductive death; sister chromatid exchange (SCE) assay to detect the exchange of DNA between sister chromatids; γH2AX assay to analyze DNA damage repair; and apoptosis analysis to compare cell death response. The advantages and limitations of these assays were assessed Results: Results from the clonogenic assay indicated that the pMMR cell line (HT29) was significantly more radio-resistant than the dMMR cell lines (HCT116, SW48, and LoVo) after 2 Gy X-irradiation. Both cell type and radiation dose had a significant effect on the yield of SCEs/chromosome. When the yield of SCEs/chromosome for the irradiated samples (2 Gy) was normalized against the controls, no significant difference was observed between the cell lines. For the γH2AX assay, 0, 20 mGy and 2 Gy were examined at post-exposure time points of 30 min (min), 4 and 24 h (h). Statistical analysis revealed that HT29 was only significantly more radio-resistant than the Discussion: Overall, this study showed radio-resistance of the MMR proficient cell line in some assays, but not in the others. All methods used within this study have been validated; however, due to the limitations associated with cancer cell lines, the next step will be to use these assays in clinical samples in an effort to understand the biological and mechanistic effects of radiation in Lynch patients as well as the health implications.

Indexed as

Brain NeoplasmsColorectal NeoplasmsColorectal Neoplasms, Hereditary NonpolyposisNeoplastic Syndromes, HereditaryCell LineHumansPilot ProjectsRadiation Tolerancecolorectal cancer cell linesLynch syndromemismatch repair (MMR) deficiencyradiation effectsradiosensitivity

Identifiers

PMID38638480
PMCPMC11024246
OpenAlexW4393944961

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.